Protein glycosylation in cancer

Annual Review of Pathology: Mechanisms of Disease

Volumn 10, Issue , 2015, Pages 473-510

  Stowell, Sean R ^a   Ju, Tongzhong ^a   Cummings, Richard D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; cancer; glycans; glycoprotein; glycosylation; immunohistochemistry; oligosaccharides; transformation

Indexed keywords

CHAPERONE; GLYCOPROTEIN; GLYCOSYLTRANSFERASE; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; ANIMAL; CELL TRANSFORMATION; GENETIC EPIGENESIS; GENETICS; GLYCOSYLATION; METABOLISM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; GLYCOSYLATION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84921930328     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012414-040438     Document Type: Article

References (297)

1. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-49
2. Fuster MM, Esko JD. 2005. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5:526-42
3. Jones PA, Laird PW. 1999. Cancer epigenetics comes of age. Nat. Genet. 21:163-67
4. Cummings RD, Pierce JM. 2014. The challenge and promise of glycomics. Chem. Biol. 21:1-15
5. Hunter T. 2012. Why nature chose phosphate to modify proteins. Philos. Trans. R. Soc. B 367:2513-16
6. Bucala R, Cerami A. 1992. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv. Pharmacol. 23:1-34
7. Wautier JL, Schmidt AM. 2004. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95:233-38
8. Marth JD, Grewal PK. 2008. Mammalian glycosylation in immunity. Nat. Rev. Immunol. 8:874-87
9. Moremen KW, Tiemeyer M, Nairn AV. 2012. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13:448-62
10. Gorelik E, Galili U, Raz A. 2001. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev. 20:245-77
11. Schwarz HP, Dorner F. 2003. Karl Landsteiner and his major contributions to haematology. Br. J. Haematol. 121:556-65
12. Stowell SR, Winkler AM, Maier CL, Arthur CM, Smith NH, et al. 2012. Initiation and regulation of complement during hemolytic transfusion reactions. Clin. Dev. Immunol. 2012:307093
13. Morgan WT, Watkins WM. 1953. The inhibition of the haemagglutinins in plant seeds by human blood group substances and simple sugars. Br. J. Exp. Pathol. 34:94-103
14. Cummings RD. 2009. The repertoire of glycan determinants in the human glycome. Mol. Biosyst. 5:1087-104
15. Freeze HH, Aebi M. 2005. Altered glycan structures: the molecular basis of congenital disorders of glycosylation. Curr. Opin. Struct. Biol. 15:490-98
16. Neufeld EF. 1991. Lysosomal storage diseases. Annu. Rev. Biochem. 60:257-80
17. Ohtsubo K, Marth JD. 2006. Glycosylation in cellular mechanisms of health and disease. Cell 126:855-67
18. de Waard A, Hickman S, Kornfeld S. 1976. Isolation and properties of β-galactoside binding lectins of calf heart and lung. J. Biol. Chem. 251:7581-87
19. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. 2005. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat. Methods 2:817-24
20. Liu FT, Rabinovich GA. 2005. Galectins asmodulators of tumour progression. Nat. Rev. Cancer 5:29-41
21. Arthur CM, Baruffi MD, Cummings RD, Stowell SR. 2015. Evolving mechanistic insights into galectin functions. Methods Mol. Biol. 1207:1-35
22. Boersema PJ, Geiger T, Wisniewski JR, Mann M. 2013. Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples. Mol. Cell. Proteomics 12:158-71
23. Slade PG, Hajivandi M, Bartel CM, Gorfien SF. 2012. Identifying theCHOsecretome using mucin-Type O-linked glycosylation and click-chemistry. J. Proteome Res. 11:6175-86
24. Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, et al. 2013. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. 32:1478-88
25. Hanisch FG, Breloy I. 2009. Protein-specific glycosylation: signal patches and cis-controlling peptidic elements. Biol. Chem. 390:619-26
26. Finne J, Finne U, Deagostini-Bazin H, Goridis C. 1983. Occurrence of α2-8 linked polysialosyl units in a neural cell adhesion molecule. Biochem. Biophys. Res. Commun. 112:482-87
27. Muhlenhoff M, Rollenhagen M, Werneburg S, Gerardy-Schahn R, Hildebrandt H. 2013. Polysialic acid: versatile modification of NCAM, SynCAM 1 and neuropilin-2. Neurochem. Res. 38:1134-43
28. Foley DA, Swartzentruber KG, Lavie A, Colley KJ. 2010. Structure and mutagenesis of neural cell adhesion molecule domains: evidence for flexibility in the placement of polysialic acid attachment sites. J. Biol. Chem. 285:27360-71
29. Rollenhagen M, Buettner FF, Reismann M, Jirmo AC, Grove M, et al. 2013. Polysialic acid on neuropilin-2 is exclusively synthesized by the polysialyltransferase ST8SiaIV and attached to mucin-Type O-glycans located between the b2 and c domain. J. Biol. Chem. 288:22880-92
30. Endo T. 2004. Structure, function and pathology of O-mannosyl glycans. Glycoconj. J. 21:3-7
31. Yoshida-Moriguchi T, Willer T, Anderson ME, Venzke D, Whyte T, et al. 2013. SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 341:896-99
32. Inamori K, Yoshida-Moriguchi T, Hara Y, Anderson ME, Yu L, Campbell KP. 2012. Dystroglycan function requires xylosyl-And glucuronyltransferase activities of LARGE. Science 335:93-96
33. Kornfeld S, Mellman I. 1989. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5:483-525
34. Dell A, Galadari A, Sastre F, Hitchen P. 2010. Similarities and differences in the glycosylation mechanisms in prokaryotes and eukaryotes. Int. J. Microbiol. 2010:148178
35. Bourdon MA, Krusius T, Campbell S, Schwartz NB, Ruoslahti E. 1987. Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. PNAS 84:3194-98
36. Doucey MA, Hess D, Cacan R, Hofsteenge J. 1998. Protein C-mannosylation is enzyme-catalysed and uses dolichyl-phosphate-mannose as a precursor. Mol. Biol. Cell 9:291-300
37. Buettner FF, Ashikov A, Tiemann B, Lehle L, Bakker H. 2013. C. Elegans DPY-19 is a Cmannosyltransferase glycosylating thrombospondin repeats. Mol. Cell 50:295-302
38. Puig B, Altmeppen H, Glatzel M. 2014. The GPI-Anchoring of PrP: implications in sorting and pathogenesis. Prion 8:11-18
39. Tsai YH, Liu X, Seeberger PH. 2012. Chemical biology of glycosylphosphatidylinositol anchors. Angew. Chem. Int. Ed. Engl. 51:11438-56
40. Orlean P, Menon AK. 2007. Thematic review series: lipid posttranslationalmodifications.GPI anchoring of protein in yeast andmammalian cells, or: howwe learned to stop worrying and love glycophospholipids. J. Lipid Res. 48:993-1011
41. Lommel M, Strahl S. 2009. Protein O-mannosylation: conserved from bacteria to humans. Glycobiology 19:816-28
42. Stanley P, Okajima T. 2010. Roles of glycosylation in Notch signaling. Curr. Top. Dev. Biol. 92:131-64
43. Leonhard-Melief C, Haltiwanger RS. 2010. O-Fucosylation of thrombospondin type 1 repeats. Methods Enzymol. 480:401-16
44. Takeuchi H, Haltiwanger RS. 2013. Enzymatic analysis of the protein O-glycosyltransferase, Rumi, acting toward epidermal growth factor-like (EGF) repeats. Methods Mol. Biol. 1022:119-28
45. Song E, Mechref Y. 2013. LC-MS/MS identification of the O-glycosylation and hydroxylation of amino acid residues of collagen α-1 (II) chain from bovine cartilage. J. Proteome Res. 12:3599-609
46. Spiro RG. 1969. Characterization and quantitative determination of the hydroxylysine-linked carbohydrate units of several collagens. J. Biol. Chem. 244:602-12
47. Schegg B, Hulsmeier AJ, Rutschmann C, Maag C, Hennet T. 2009. Core glycosylation of collagen is initiated by two β(1-O)galactosyltransferases. Mol. Cell. Biol. 29:943-52
48. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. 2011. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80:825-58
49. Bond MR, Hanover JA. 2013. O-GlcNAc cycling: a link between metabolism and chronic disease. Annu. Rev. Nutr. 33:205-29
50. Love DC, Kochan J, Cathey RL, Shin SH, Hanover JA. 2003. Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J. Cell Sci. 116:647-54
51. Cao W, Cao J, Huang J, Yao J, Yan G, et al. 2013. Discovery and confirmation of O-GlcNAcylated proteins in rat liver mitochondria by combination of mass spectrometry and immunological methods. PLOS ONE 8:e76399
52. Sakaidani Y, Nomura T, Matsuura A, Ito M, Suzuki E, et al. 2011. O-Linked-N-Acetylglucosamine on extracellular protein domains mediates epithelial cell-matrix interactions. Nat. Commun. 2:583
53. Slawson C, Hart GW. 2011. O-GlcNAc signalling: implications for cancer cell biology. Nat. Rev. Cancer 11:678-84
54. Lomako J, Lomako WM, Whelan WJ. 1988. A self-glucosylating protein is the primer for rabbit muscle glycogen biosynthesis. FASEB J. 2:3097-103
55. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. 2012. Glycogen and its metabolism: some new developments and old themes. Biochem. J. 441:763-87
56. Hauselmann I, Borsig L. 2014. Altered tumor-cell glycosylation promotes metastasis. Front. Oncol. 4:28
57. Lau KS, Dennis JW. 2008. N-Glycans in cancer progression. Glycobiology 18:750-60
58. Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. 2014. Cell surface protein glycosylation in cancer. Proteomics 14:525-46
59. Dube DH, Bertozzi CR. 2005. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4:477-88
60. Brooks SA, Carter TM, Royle L, Harvey DJ, Fry SA, et al. 2008. Altered glycosylation of proteins in cancer: What is the potential for new anti-Tumour strategies. Anti-Cancer Agents Med. Chem. 8:2-21
61. Song EY, Kang SK, Lee YC, Park YG, Chung TH, et al. 2001. Expression of bisecting Nacetylglucosaminyltransferase-III in human hepatocarcinoma tissues, fetal liver tissues, and hepatoma cell lines of Hep3B and HepG2. Cancer Investig. 19:799-807
62. Mori S, Aoyagi Y, Yanagi M, Suzuki Y, Asakura H. 1998. Serum N-Acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 13:610-19
63. Ogawa J, Inoue H, Koide S. 1996. Expression ofα-1, 3-fucosyltransferase type IVand VII genes is related to poor prognosis in lung cancer. Cancer Res. 56:325-29
64. Togayachi A, Kudo T, Ikehara Y, Iwasaki H, Nishihara S, et al. 1999. Up-regulation of Lewis enzyme (Fuc-TIII) and plasma-Type α1, 3fucosyltransferase (Fuc-TVI) expression determines the augmented expression of sialyl Lewis x antigen in non-small cell lung cancer. Int. J. Cancer 83:70-79
65. Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, et al. 2011. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res. 71:7683-93
66. Bresalier RS, Ho SB, Schoeppner HL, Kim YS, Sleisenger MH, et al. 1996. Enhanced sialylation of mucin-Associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 110:1354-67
67. Ishida H, Togayachi A, Sakai T, Iwai T, Hiruma T, et al. 2005. A novel β1, 3-Nacetylglucosaminyltransferase (β3Gn-T8), which synthesizes poly-N-Acetyllactosamine, is dramatically upregulated in colon cancer. FEBS Lett. 579:71-78
68. McManus JF. 1948. Histological and histochemical uses of periodic acid. Stain Technol. 23:99-108
69. Hakomori S. 1989. Aberrant glycosylation in tumors and tumor-Associated carbohydrate antigens. Adv. Cancer Res. 52:257-331
70. Warnock ML, Stoloff A, Thor A. 1988. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am. J. Pathol. 133:30-8
71. Bochner BS, Alvarez RA, Mehta P, Bovin NV, Blixt O, et al. 2005. Glycan array screening reveals a candidate ligand for Siglec-8. J. Biol. Chem. 280:4307-12
72. Arthur CM, Rodrigues LC, Baruffi MD, Sullivan HC, Heimburg-Molinaro J, et al. 2015. Examining galectin binding specificity using glycan microarrays. Methods Mol. Biol. 1207:115-31
73. Song X, Xia B, Stowell SR, Lasanajak Y, Smith DF, Cummings RD. 2009. Novel fluorescent glycan microarray strategy reveals ligands for galectins. Chem. Biol. 16:36-47
74. Arthur CM, Cummings RD, Stowell SR. 2014. Using glycan microarrays to understand immunity. Curr. Opin. Chem. Biol. 18:55-61
75. Rillahan CD, Paulson JC. 2011. Glycan microarrays for decoding the glycome. Annu. Rev. Biochem. 80:797-823
76. Borgert A, Heimburg-Molinaro J, SongX, Lasanajak Y, Ju T, et al. 2012. Deciphering structural elements of mucin glycoprotein recognition. ACS Chem. Biol. 7:1031-39
77. Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, et al. 2011. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 128:1860-71
78. Marcus DM, Perry L, Gilbert S, Preud'homme JL, Kyle R. 1989. Human IgM monoclonal proteins that bind 3-fucosyllactosamine, asialo-GM1, and GM1. J. Immunol. 143:2929-32
79. Hong X, Ma MZ, Gildersleeve JC, Chowdhury S, Barchi JJ Jr, et al. 2013. Sugar-binding proteins from fish: selection of high affinity 'lambodies' that recognize biomedically relevant glycans. ACS Chem. Biol. 8:152-60
80. Yu C, Ali S, St. Germain J, Liu Y, Yu X, et al. 2012. Purification and identification of cell surface antigens using lamprey monoclonal antibodies. J. Immunol. Methods 386:43-49
81. Han BW, Herrin BR, Cooper MD, Wilson IA. 2008. Antigen recognition by variable lymphocyte receptors. Science 321:1834-37
82. Morelle W, Michalski JC. 2007. Analysis of protein glycosylation by mass spectrometry. Nat. Protoc. 2:1585-602
83. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, et al. 1989. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 49:197-204
84. Werther JL, Rivera-MacMurray S, Bruckner H, Tatematsu M, Itzkowitz SH. 1994. Mucin-Associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome.Br. J. Cancer 69:613-16
85. Yamada T, Watanabe A, Yamada Y, Shino Y, Tanase M, et al. 1995. Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer. Cancer 76:1529-36
86. Coon JS, Weinstein RS, Summers JL. 1982. Blood group precursor T-Antigen expression in human urinary bladder carcinoma. Am. J. Clin. Pathol. 77:692-99
87. Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. 1995. Expression of sialyl Lewisa as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 75:2051-56
88. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, et al. 1993. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 53:3632-37
89. Ogawa J, Sano A, Inoue H, Koide S. 1995. Expression of Lewis-related antigen and prognosis in stage I non-small cell lung cancer. Ann. Thorac. Surg. 59:412-15
90. Nakagoe T, Fukushima K, Nanashima A, Sawai T, Tsuji T, et al. 2001. Comparison of the expression of ABH/Lewis-related antigens in polypoid and non-polypoid growth types of colorectal carcinoma. J. Gastroenterol. Hepatol. 16:176-83
91. Jorgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. 1995. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res. 55:1817-19
92. Yago K, Zenita K, Ginya H, Sawada M, Ohmori K, et al. 1993. Expression of α-(1, 3)-fucosyltransferases which synthesize sialyl Lex and sialyl Lea, the carbohydrate ligands for E-And P-selectins, in human malignant cell lines. Cancer Res. 53:5559-65
93. Walz G, Aruffo A, Kolanus W, Bevilacqua M, Seed B. 1990. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science 250:1132-35
94. Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, et al. 1990. ELAM-1mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 250:1130-32
95. Lowe JB, Stoolman LM, Nair RP, Larsen RD, Berhend TL, Marks RM. 1990. ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA. Cell 63:475-84
96. Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, et al. 2009. Alpha 1, 3 fucosyltransferases are master regulators of prostate cancer cell trafficking. PNAS 106:19491-96
97. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. 2002. Synergistic effects of L-And P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. PNAS 99:2193-98
98. Kim YJ, Borsig L, Varki NM, Varki A. 1998. P-selectin deficiency attenuates tumor growth and metastasis. PNAS 95:9325-30
99. Lee JS, Ro JY, Sahin AA, Hong WK, Brown BW, et al. 1991. Expression of blood-group antigen A-A favorable prognostic factor in non-small-cell lung cancer. N. Engl. J. Med. 324:1084-90
100. Biondi C, Campi C, Escovich L, Garcia Borras S, Racca A, Cotorruelo C. 2008. Loss of A, B and H antigens in oral cancer. Immunologia 27:127-31
101. Newman AJ Jr, Carlton CE Jr, Johnson S. 1980. Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J. Urol. 124:27-29
102. Ju T, Aryal RP, Kudelka MR, Wang Y, Cummings RD. 2014. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 14:63-81
103. Peracaula R, Barrabes S, Sarrats A, Rudd PM, de Llorens R. 2008. Altered glycosylation in tumours focused to cancer diagnosis. Dis. Markers 25:207-18
104. Goonetilleke KS, Siriwardena AK. 2007. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 33:266-70
105. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. 1979. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 5:957-71
106. Ballehaninna UK, Chamberlain RS. 2012. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J. Gastrointest. Oncol. 3:105-19
107. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. 1981. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Investig. 68:1331-37
108. Yin BW, Lloyd KO. 2001. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276:27371-75
109. Su Z, Graybill WS, Zhu Y. 2013. Detection and monitoring of ovarian cancer. Clin. Chim. Acta 415:341-45
110. Hammarstrom S. 1999. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9:67-81
111. Duffy MJ. 2001. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?. Clin. Chem. 47:624-30
112. Ward AM, Catto JW, Hamdy FC. 2001. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann. Clin. Biochem. 38:633-51
113. Lilja H, Ulmert D, Vickers AJ. 2008. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8:268-78
114. Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O'Kennedy RJ. 2013. Aberrant PSA glycosylation-A sweet predictor of prostate cancer. Nat. Rev. Urol. 10:99-107
115. Terentiev AA, Moldogazieva NT. 2013. Alpha-fetoprotein: a renaissance. Tumour Biol. 34:2075-91
116. Moriya S, Morimoto M, Numata K, Nozaki A, Shimoyama Y, et al. 2013. Fucosylated fraction of alphafetoprotein as a serological marker of early hepatocellular carcinoma. Anticancer Res. 33:997-1001
117. Hiraoka A, Nakahara H, Kawasaki H, Shimizu Y, Hidaka S, et al. 2012. Huge pancreatic acinar cell carcinoma with high levels of AFP and fucosylated AFP (AFP-L3). Intern. Med. 51:1341-49
118. Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. 2008. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 68:3803-9
119. Kumler I, Tuxen MK, Nielsen DL. 2014. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat. Rev. 40:259-70
120. Cole LA, Butler SA. 2008. Hyperglycosylated human chorionic gonadotropin and human chorionic gonadotropin free β-subunit: tumor markers and tumor promoters. J. Reprod. Med. 53:499-512
121. Gendler SJ. 2001. MUC1, the renaissance molecule. J. Mamm. Gland Biol. Neoplasia 6:339-53
122. HollingsworthMA, Swanson BJ. 2004. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4:45-60
123. Ju T, Otto VI, Cummings RD. 2011. The Tn antigen-structural simplicity and biological complexity. Angew. Chem. Int. Ed. 50:1770-91
124. Ju T, Wang Y, Aryal RP, Lehoux SD, Ding X, et al. 2013. Tn and sialyl-Tn antigens, aberrant Oglycomics as human disease markers. Proteomics Clin. Appl. 7:618-31
125. O'Boyle KP, Markowitz AL, Khorshidi M, Lalezari P, Longenecker BM, et al. 1996. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-6) T antigens. Hybridoma 15:401-8
126. Hanisch FG, Uhlenbruck G, Egge H, Peter-Katalinic J. 1989. A B72.3 second-generation-monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Galβ(1-3) [NeuAcα(2-6)]GalNAc. Biol. Chem. 370:21-26
127. Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, et al. 2007. Population pharmacokinetics of humanized monoclonal antibody HuCC49-CH2 and murine antibody CC49 in colorectal cancer patients. J. Clin. Pharmacol. 47:227-37
128. Zhao P, Nairn AV, Hester S, Moremen KW, O'Regan RM, et al. 2012. Proteomic identification of glycosylphosphatidylinositol anchor-dependent membrane proteins elevated in breast carcinoma. J. Biol. Chem. 287:25230-40
129. Dolezal S, Hester S, Kirby PS, Nairn A, Pierce M, Abbott KL. 2014. Elevated levels of glycosylphosphatidylinositol (GPI) anchored proteins in plasma from human cancers detected by C. septicum alpha toxin. Cancer Biomark. 14:55-62
130. Varki A. 2010. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. PNAS 107(Suppl. 2):8939-46
131. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, et al. 2011. Human xeno-Autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res. 71:3352-63
132. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, et al. 2008. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 68:1636-46
133. Guda K, Moinova H, He J, Jamison O, Ravi L, et al. 2009. Inactivating germ-line and somatic mutations in polypeptide N-Acetylgalactosaminyltransferase 12 in human colon cancers. PNAS 106:12921-25
134. Chen L, Zhang W, Fregien N, Pierce M. 1998. The her-2/neu oncogene stimulates the transcription of N-Acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. Oncogene 17:2087-93
135. Noda K, Miyoshi E, Uozumi N, Yanagidani S, Ikeda Y, et al. 1998. Gene expression of α1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation ofα-fetoprotein. Hepatology 28:944-52
136. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, et al. 2010. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-Acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 70:2759-69
137. Gomes J, Marcos NT, Berois N, Osinaga E, Magalhaes A, et al. 2009. Expression of UDP-N-Acetyl-Dgalactosamine: polypeptideN-Acetylgalactosaminyltransferase-6 in gastric mucosa, intestinalmetaplasia, and gastric carcinoma. J. Histochem. Cytochem. 57:79-86
138. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, et al. 2007. Death-receptor Oglycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13:1070-77
139. Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, et al. 2006. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-Associated sialyl-Tn O-glycan in human breast cancer. J. Biol. Chem. 281:3586-94
140. Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, et al. 2014. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. PNAS 111:E4066-75
141. Mi R, Song L, Wang Y, Ding X, Zeng J, et al. 2012. Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing Tn antigen. J. Biol. Chem. 287:41523-33
142. Huang J, Che MI, Lin NY, Hung JS, Huang YT, et al. 2014. The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK. Mol. Carcinog. 53(Suppl. 1):E62-71
143. Hung JS, Huang J, Lin YC, Huang MJ, Lee PH, et al. 2014. C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2. Oncotarget 5:2096-106
144. Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH, et al. 2013. C1GALT1 enhances proliferation of hepatocellular carcinoma cells viamodulatingMETglycosylation and dimerization. Cancer Res. 73:5580-90
145. Liu CH, Hu RH, Huang MJ, Lai IR, Chen CH, et al. 2014. C1GALT1 promotes invasive phenotypes of hepatocellular carcinoma cells by modulating integrin β1 glycosylation and activity. PLOS ONE 9:e94995
146. Hakomori S. 1999. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim. Biophys. Acta 1473:247-66
147. Dabelsteen E, Gao S. 2005. ABO blood-group antigens in oral cancer. J. Dent. Res. 84:21-28
148. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, et al. 2005. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. PNAS 102:4572-77
149. Malagolini N, Dall'Olio F, Di Stefano G, Minni F, Marrano D, Serafini-Cessi F. 1989. Expression of UDP-GalNAc:NeuAcα2, 3Galβ-Rβ1, 4(GalNAc to Gal) N-Acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas. Cancer Res. 49:6466-70
150. Karasawa F, Shiota A, Goso Y, Kobayashi M, Sato Y, et al. 2012. Essential role of gastric gland mucin in preventing gastric cancer in mice. J. Clin. Investig. 122:923-34
151. Tu L, Banfield DK. 2010. Localization ofGolgi-resident glycosyltransferases. Cell. Mol. Life Sci. 67:29-41
152. Gill DJ, Chia J, Senewiratne J, Bard F. 2010. Regulation of O-glycosylation through Golgi-To-ER relocation of initiation enzymes. J. Cell Biol. 189:843-58
153. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16
154. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, et al. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Investig. 104:155-62
155. Shimodaira K, Nakayama J, Nakamura N, Hasebe O, Katsuyama T, Fukuda M. 1997. Carcinomaassociated expression of core 2 β-1, 6-N-Acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res. 57:5201-6
156. Julien S, Lagadec C, Krzewinski-Recchi MA, Courtand G, Le Bourhis X, Delannoy P. 2005. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res. Treat. 90:77-84
157. Wang Y, Jobe SM, Ding X, Choo H, Archer DR, et al. 2012. Platelet biogenesis and functions require correct protein O-glycosylation. PNAS 109:16143-48
158. Lu Y, Chaney W. 1993. Induction of N-Acetylglucosaminyltransferase V by elevated expression of activated or proto-Ha-ras oncogenes. Mol. Cell. Biochem. 122:85-92
159. Dennis JW, Kosh K, Bryce DM, Breitman ML. 1989. Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. Oncogene 4:853-60
160. Demetriou M, Nabi IR, Coppolino M, Dedhar S, Dennis JW. 1995. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-Transferase V. J. Cell Biol. 130:383-92
161. Yamamoto H, Swoger J, Greene S, Saito T, Hurh J, et al. 2000. β1, 6-N-Acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity. Cancer Res. 60:134-42
162. Kim YS, Ahn YH, Song KJ, Kang JG, Lee JH, et al. 2012. Overexpression and β-1, 6-Nacetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a 'double whammy' strategy in colon cancer progression. J. Biol. Chem. 287:32467-78
163. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68
164. Inamori K, Gu J, Ohira M, Kawasaki A, Nakamura Y, et al. 2006. High expression of Nacetylglucosaminyltransferase V in favorable neuroblastomas: involvement of its effect on apoptosis. FEBS Lett. 580:627-32
165. Rebbaa A, Yamamoto H, Saito T, Meuillet E, Kim P, et al. 1997. Gene transfection-mediated overexpression of β1, 4-N-Acetylglucosamine bisecting oligosaccharides in glioma cell line U373 MG inhibits epidermal growth factor receptor function. J. Biol. Chem. 272:9275-79
166. Yokoe S, Takahashi M, Asahi M, Lee SH, Li W, et al. 2007. The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion. Cancer Res. 67:1935-42
167. Semel AC, Seales EC, Singhal A, Eklund EA, Colley KJ, Bellis SL. 2002. Hyposialylation of integrins stimulates the activity of myeloid fibronectin receptors. J. Biol. Chem. 277:32830-36
168. Dennis J, Waller C, Timpl R, Schirrmacher V. 1982. Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. Nature 300:274-76
169. Nadanaka S, Sato C, Kitajima K, Katagiri K, Irie S, Yamagata T. 2001. Occurrence of oligosialic acids on integrinα5 subunit and their involvement in cell adhesion to fibronectin. J. Biol. Chem. 276:33657-64
170. Liu YC, Yen HY, Chen CY, Chen CH, Cheng PF, et al. 2011. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. PNAS 108:11332-37
171. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, et al. 2008. The role of the EGFR signaling in tumor microenvironment. J. Cell. Physiol. 214:559-67
172. Meuillet EJ, Kroes R, Yamamoto H, Warner TG, Ferrari J, et al. 1999. Sialidase gene transfection enhances epidermal growth factor receptor activity in an epidermoid carcinoma cell line, A431. Cancer Res. 59:234-40
173. Kroes RA, He H, Emmett MR, Nilsson CL, Leach FE III, et al. 2010. Overexpression of ST6GalNAcV, a ganglioside-specific α2, 6-sialyltransferase, inhibits glioma growth in vivo. PNAS 107:12646-51
174. Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, et al. 2013. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. PNAS 110:630-35
175. Saeland E, van Vliet SJ, Backstrom M, van den Berg VC, Geijtenbeek TB, et al. 2007. The C-Type lectin MGLexpressed by dendritic cells detects glycan changes onMUC1 in colon carcinoma. Cancer Immunol. Immunother. 56:1225-36
176. Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, et al. 2007. Tumor-Associated Tn-MUC1 glycoform is internalized through themacrophage galactose-TypeC-Type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res. 67:8358-67
177. van Vliet SJ, Bay S, Vuist IM, Kalay H, Garcia-Vallejo JJ, et al. 2013. MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-αsecretion. J. Leukoc. Biol. 94:315-23
178. Ogata S, Maimonis PJ, Itzkowitz SH. 1992. Mucins bearing the cancer-Associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res. 52:4741-46
179. Engering A, Geijtenbeek TB, van Kooyk Y. 2002. Immune escape through C-Type lectins on dendritic cells. Trends Immunol. 23:480-85
180. Fukumori T, Takenaka Y, Oka N, Yoshii T, Hogan V, et al. 2004. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res. 64:3376-79
181. Stowell SR, Arthur CM, Dias-BaruffiM, Rodrigues LC, Gourdine JP, et al. 2010. Innate immune lectins kill bacteria expressing blood group antigen. Nat. Med. 16:295-301
182. van Vliet SJ, den Dunnen J, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. 2007. Innate signaling and regulation of dendritic cell immunity. Curr. Opin. Immunol. 19:435-40
183. Stowell SR, Arthur CM, McBride R, Berger O, Razi N, et al. 2014. Microbial glycan microarrays define key features of host-microbial interactions. Nat. Chem. Biol. 10:470-76
184. Soldati R, Berger E, Zenclussen AC, Jorch G, Lode HN, et al. 2012. Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int. J. Cancer 131:1131-41
185. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, et al. 2013. Targeting galectin-1 overcomes breast cancer-Associated immunosuppression and prevents metastatic disease. Cancer Res. 73:1107-17
186. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, et al. 2014. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156:744-58
187. Stowell SR, Karmakar S, Stowell CJ, Dias-Baruffi M, McEver RP, Cummings RD. 2007. Human galectin-1,-2, and-4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109:219-27
188. Stowell SR, Qian Y, Karmakar S, Koyama NS, Dias-BaruffiM, et al. 2008. Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J. Immunol. 180:3091-102
189. Furtak V, Hatcher F, Ochieng J. 2001. Galectin-3 mediates the endocytosis of β-1 integrins by breast carcinoma cells. Biochem. Biophys. Res. Commun. 289:845-50
190. Fukushi J, Makagiansar IT, Stallcup WB. 2004. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and α3β1 integrin. Mol. Biol. Cell 15:3580-90
191. D'Haene N, Sauvage S, Maris C, Adanja I, Le Mercier M, et al. 2013. VEGFR1 and VEGFR2 involvement in extracellular galectin-1-And galectin-3-induced angiogenesis. PLOS ONE 8:e67029
192. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, et al. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 156:899-909
193. Dennis JW, Koch K, Yousefi S, VanderElst I. 1990. Growth inhibition of human melanoma tumor xenografts in athymic nude mice by swainsonine. Cancer Res. 50:1867-72
194. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med. 6:306-12
195. Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N. 1995. Suppression of lung metastasis of B16 mouse melanoma by N-Acetylglucosaminyltransferase III gene transfection. PNAS 92:8754-58
196. Yamamoto H, Oviedo A, Sweeley C, Saito T, Moskal JR. 2001.α2, 6-Sialylation of cell-surfaceN-glycans inhibits glioma formation in vivo. Cancer Res. 61:6822-29
197. Petretti T, Kemmner W, Schulze B, Schlag PM. 2000. AlteredmRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Gut 46:359-66
198. Kojima N, Handa K, Newman W, Hakomori S. 1992. Inhibition of selectin-dependent tumor cell adhesion to endothelial cells and platelets by blocking O-glycosylation of these cells. Biochem. Biophys. Res. Commun. 182:1288-95
199. Ohyama C, Tsuboi S, Fukuda M. 1999. Dual roles of sialyl Lewis X oligosaccharides in tumormetastasis and rejection by natural killer cells. EMBO J. 18:1516-25
200. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. 2002. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J. Immunol. 168:1813-22
201. Sarafian V, Jadot M, Foidart JM, Letesson JJ, Van den Brule F, et al. 1998. Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. Int. J. Cancer 75:105-11
202. Lotan R, Raz A. 1983. Low colony formation in vivo and in culture as exhibited by metastatic melanoma cells selected for reduced homotypic aggregation. Cancer Res. 43:2088-93
203. Takenaka Y, Fukumori T, Raz A. 2004. Galectin-3 and metastasis. Glycoconj. J. 19:543-49
204. Liu FT, Patterson RJ, Wang JL. 2002. Intracellular functions of galectins. Biochim. Biophys. Acta 1572:263-73
205. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, et al. 2012. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J. Exp. Med. 209:1985-2000
206. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. 2003. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Investig. 112:853-62
207. Shao B, Wahrenbrock MG, Yao L, David T, Coughlin SR, et al. 2011. Carcinomamucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood 118:4015-23
208. Samraj AN, Laubli H, Varki N, Varki A. 2014. Involvement of a non-human sialic acid in human cancer. Front. Oncol. 4:33
209. Heneghan MA, McCarthy CF, Janulaityte D, Moran AP. 2001. Relationship of anti-Lewis x and anti-Lewis y antibodies in serum samples from gastric cancer and chronic gastritis patients to Helicobacter pylori-mediated autoimmunity. Infect. Immun. 69:4774-81
210. Hunter T. 2007. Treatment for chronic myelogenous leukemia: the long road to imatinib. J. Clin. Investig. 117:2036-43
211. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353:1659-72
212. Hakomori S. 2001. Tumor-Associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491:369-402
213. Springer GF, Desai PR, Spencer BD, Tegtmeyer H, Carlstedt SC, Scanlon EF. 1995. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Cancer Detect. Prev. 19:374-80
214. Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, et al. 2005. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54:694-702
215. Miles D, Roche H, Martin M, Perren TJ, Cameron DA, et al. 2011. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16:1092-100
216. Ju T, CummingsRD. 2002.A unique molecular chaperoneCosmc required for activity of the mammalian core 1 β3-galactosyltransferase. PNAS 99:16613-18
217. Schjoldager KT, Vakhrushev SY, Kong Y, Steentoft C, Nudelman AS, et al. 2012. Probing isoformspecific functions of polypeptide GalNAc-Transferases using zinc finger nuclease glycoengineered SimpleCells. PNAS 109:9893-98
218. Ikehara Y, Kojima N, Kurosawa N, Kudo T, Kono M, et al. 1999. Cloning and expression of a human gene encoding an N-Acetylgalactosamine-α2, 6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-Associated sialyl-Tn antigens. Glycobiology 9:1213-24
219. Brockhausen I, Yang J, Dickinson N, Ogata S, Itzkowitz SH. 1998. Enzymatic basis for sialyl-Tn expression in human colon cancer cells. Glycoconj. J. 15:595-603
220. Almaraz RT, Tian Y, Bhattarcharya R, Tan E, Chen SH, et al. 2012. Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Mol. Cell. Proteomics 11:M112.017558
221. Almaraz RT, Aich U, Khanna HS, Tan E, Bhattacharya R, et al. 2012. Metabolic oligosaccharide engineering with N-Acyl functionalized ManNAc analogs: cytotoxicity, metabolic flux, and glycan-display considerations. Biotechnol. Bioeng. 109:992-1006
222. Bull C, Boltje TJ, Wassink M, de Graaf AM, van Delft FL, et al. 2013. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol. Cancer Ther. 12:1935-46
223. Sampathkumar SG, Jones MB, Meledeo MA, Campbell CT, Choi SS, et al. 2006. Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. Chem. Biol. 13:1265-75
224. Duan X, Cai L, Lee LA, Chen H, Wang Q. 2013. Incorporation of azide sugar analogue decreases tumorigenic potential of breast cancer cells by reducing cancer stem cell population. Sci. China Chem. 56:279-85
225. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. 2007. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin. Ther. Targets 11:1473-91
226. Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, et al. 2000. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res. 60:450-56
227. Watkins WM, Morgan WT. 1952. Neutralization of the anti-H agglutinin in eel serum by simple sugars. Nature 169:825-26
228. Kabat EA, Leskowitz S. 1955. Immunochemical studies on blood group. XVII. Structural units involved in blood group A and B specificity. J. Am. Chem. Soc. 77:5159-64
229. Kabat EA, Schiffman G. 1962. Immunochemical studies on blood groups. XXVIII. Further studies on the oligosaccharide determinants of blood group B and BP1 specificity. J. Immunol. 88:782-87
230. Nowell PC. 1960. Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes. Cancer Res. 20:462-66
231. Kornfeld S, Kornfeld R. 1969. Solubilization and partial characterization of a phytohemagglutinin receptor site from human erythrocytes. PNAS 63:1439-46
232. Gesner BM, Ginsburg V. 1964. Effect of glycosidases on the fate of transfused lymphocytes. PNAS 52:750-55
233. PricerWE Jr, Hudgin RL, Ashwell G, Stockert RJ, Morell AG. 1974. A membrane receptor protein for asialoglycoproteins. Methods Enzymol. 34:688-91
234. Hudgin RL, PricerWE Jr, Ashwell G, Stockert RJ, Morell AG. 1974. The isolation and properties of a rabbit liver binding protein specific for asialoglycoproteins. J. Biol. Chem. 249:5536-43
235. Morell AG, Van den Hamer CJ, Scheinberg IH, Ashwell G. 1966. Physical and chemical studies on ceruloplasmin. IV. Preparation of radioactive, sialic acid-free ceruloplasmin labeled with tritium on terminal D-galactose residues. J. Biol. Chem. 241:3745-49
236. Oh-Uti K. 1949. Polysaccharides and a glycidamin in the tissue of gastric cancer. Tohoku J. Exp. Med. 51:297-304
237. Gasic G, Gasic T. 1962. Removal and regeneration of the cell coating in tumour cells. Nature 196:170
238. Gasic G, Gasic T. 1962. Removal of sialic acid from the cell coat in tumor cells and vascular endothelium, and its effects on metastasis. PNAS 48:1172-77
239. Burger MM, Goldberg AR. 1967. Identification of a tumor-specific determinant on neoplastic cell surfaces. PNAS 57:359-66
240. Pollack RE, Burger MM. 1969. Surface-specific characteristics of a contact-inhibited cell line containing the SV40 viral genome. PNAS 62:1074-76
241. Burger MM. 1968. Isolation of a receptor complex for a tumor specific agglutinin from the neoplastic cell surface. Nature 219:499-500
242. Benjamin TL, Burger MM. 1970. Absence of a cell membrane alteration function in non-Transforming mutants of polyoma virus. PNAS 67:929-34
243. Inbar M, Sachs L. 1969. Structural difference in sites on the surface membrane of normal and transformed cells. Nature 223:710-12
244. Inbar M, Sachs L. 1969. Interaction of the carbohydrate-binding protein concanavalin A with normal and transformed cells. PNAS 63:1418-25
245. Aub JC, Sanford BH, Wang LH. 1965. Reactions of normal and leukemic cell surfaces to a wheat germ agglutinin. PNAS 54:400-2
246. Aub JC, Sanford BH, Cote MN. 1965. Studies on reactivity of tumor and normal cells to a wheat germ agglutinin. PNAS 54:396-99
247. Hakomori SI, Murakami WT. 1968. Glycolipids of hamster fibroblasts and derived malignanttransformed cell lines. PNAS 59:254-61
248. Buck CA, Glick MC, Warren L. 1971. Glycopeptides from the surface of control and virus-Transformed cells. Science 172:169-71
249. Meezan E, WuHC, Black PH, Robbins PW. 1969. Comparative studies on the carbohydrate-containing membrane components of normal and virus-Transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by Sephadex chromatography. Biochemistry 8:2518-24
250. Wu HC, Meezan E, Black PH, Robbins PW. 1969. Comparative studies on the carbohydrate-containing membrane components of normal and virus-Transformed mouse fibroblasts. I. Glucosamine-labeling patterns in 3T3, spontaneously transformed 3T3, and SV-40-Transformed 3T3 cells. Biochemistry 8:2509-17
251. Warren L, Buck CA, Tuszynski GP. 1978. Glycopeptide changes and malignant transformation. A possible role for carbohydrate in malignant behavior. Biochim. Biophys. Acta 516:97-127
252. Clamp JR, Jones JV. 1968. The antigenicity of the oligosaccharide units of a soluble glycoprotein. Clin. Chim. Acta 21:165-69
253. Springer GF. 1984. T and Tn, general carcinoma autoantigens. Science 224:1198-206
254. Springer GF, Desai PR, Banatwala I. 1975. Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. J. Natl. Cancer Inst. 54:335-39
255. Howard DR, Taylor CR. 1980. An antitumor antibody in normal human serum: reaction of anti-T with breast carcinoma cells. Oncology 37:142-48
256. Springer GF, Desai PR. 1977. Cross-reacting carcinoma-Associated antigens with blood group and precursor specificities. Transplant. Proc. 9:1105-11
257. Hakomori S, Wang SM, Young Jr. WW. 1977. Isoantigenic expression of Forssman glycolipid in human gastric and colonicmucosa: its possible identitywith 'A-like antigen' in human cancer.PNAS74:3023-27
258. Solter D, Knowles BB. 1978. Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). PNAS 75:5565-69
259. Knowles BB, Aden DP, Solter D. 1978. Monoclonal antibody detecting a stage-specific embryonic antigen (SSEA-1) on preimplantation mouse embryos and teratocarcinoma cells. Curr. Top. Microbiol. Immunol. 81:51-53
260. Herlyn M, Sears HF, Steplewski Z, Koprowski H. 1982. Monoclonal antibody detection of a circulating tumor-Associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J. Clin. Immunol. 2:135-40
261. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. 1983. Identification of the gastrointestinal and pancreatic cancer-Associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 43:5489-92
262. Sears HF, Herlyn M, Del Villano B, Steplewski Z, Koprowski H. 1982. Monoclonal antibody detection of a circulating tumor-Associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J. Clin. Immunol. 2:141-49
263. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB. 1983. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol. 2:275-85
264. Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, et al. 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309:883-87
265. Springer GF, Chandrasekaran EV, Desai PR, Tegtmeyer H. 1988. Blood group Tn-Active macromolecules from human carcinomas and erythrocytes: characterization of and specific reactivity with mono-And poly-clonal anti-Tn antibodies induced by various immunogens. Carbohydr. Res. 178:271-92
266. Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, et al. 1988. The fucosylation index of alphafetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 61:769-74
267. Colcher DM, Milenic DE, Schlom J. 1992. Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies. Target. Diagn. Ther. 6:23-44
268. Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J. 1982. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-Associated antigen in human mammary carcinoma cell populations. Int. J. Cancer 29:539-45
269. Colcher D, Hand PH, Nuti M, Schlom J. 1981. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. PNAS 78:3199-203
270. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Blake C, Ho SK. 2000. Structures of disease-specific serum alpha-fetoprotein isoforms. Br. J. Cancer 83:1330-37
271. Furness P. 1996. βhCG as a prognostic marker in prostatic adenocarcinoma. J. Clin. Pathol. 49:693-94
272. Yoshimoto Y, Wolfsen AR, Odell WD. 1979. Glycosylation, a variable in the production of hCG by cancers. Am. J. Med. 67:414-20
273. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, et al. 2004. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin. Chem. 50:559-63
274. Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. 2000. CA 15-3: a prognostic marker in breast cancer. Int. J. Biol. Markers 15:330-33
275. Parikh DA, Durbin-Johnson B, Urayama S. 2014. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population. J. Gastrointest. Cancer 45:74-79
276. Ballehaninna UK, Chamberlain RS. 2013. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 34:3279-92
277. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, et al. 1998. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 58:512-18
278. Beveridge RA. 1999. Review of clinical studies of CA 27.29 in breast cancer management. Int. J. Biol. Markers 14:36-39
279. Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. 2013. Exploring the glycosylation of serum CA125. Int. J. Mol. Sci. 14:15636-54
280. Petignat P, Joris F, Obrist R. 2000. How CA 125 is used in routine clinical practice. Eur. J. Cancer 36:1933-37
281. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Dorsa R, Schwartz DC. 1991. CA 549 as a marker in breast cancer. Int. J. Biol. Markers 6:139-43
282. Amri R, Bordeianou LG, Sylla P, Berger DL. 2013. Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. J. Surg. Oncol. 108:14-18
283. Salvini R, Bardoni A, Valli M, Trinchera M. 2001. β1, 3-Galactosyltransferase β3Gal-T5 acts on the GlcNAcβ1-3Galβ1-4GlcNAcβ1-R sugar chains of carcinoembryonic antigen and other N-linked glycoproteins and is down-regulated in colon adenocarcinomas. J. Biol. Chem. 276:3564-73
284. Haab BB, Porter A, YueT, LiL, Scheiman J, et al. 2010. Glycosylation variants of mucins andCEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann. Surg. 251:937-45
285. Jantscheff P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, et al. 2003. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J. Clin. Oncol. 21:3638-46
286. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. 2010. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28:92-98
287. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, et al. 2004. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell. Proteomics 3:379-98
288. Hesse E, Musholt PB, Potter E, Petrich T, Wehmeier M, et al. 2005. Oncofoetal fibronectin-A tumourspecific marker in detecting minimal residual disease in differentiated thyroid carcinoma. Br. J. Cancer 93:565-70
289. Goldsmith JD, Pawel B, Goldblum JR, Pasha TL, Roberts S, et al. 2002. Detection and diagnostic utilization of placental alkaline phosphatase in muscular tissue and tumors with myogenic differentiation. Am. J. Surg. Pathol. 26:1627-33
290. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. 1987. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317:909-16
291. Hernandez J, Thompson IM. 2004. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101:894-904
292. Moyer VA. 2012. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157:120-34
293. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, et al. 2003. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 13:457-70
294. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS. 1990. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66:1960-66
295. Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, et al. 2007. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett. 251:247-57
296. Springer GF. 1997. ImmunoreactiveTandTn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. 75:594-602
297. Aryal RP, Ju T, Cummings RD. 2014. Identification of a novel protein binding motif within the Tsynthase for the molecular chaperone Cosmc. J. Biol. Chem. 289:11630-41